PSA Screening for HIM Act
The PSA Screening for HIM Act ensures high-risk insured men receive covered prostate cancer screenings, promoting early detection and better health outcomes.
The PSA Screening for HIM Act ensures high-risk insured men receive covered prostate cancer screenings, promoting early detection and better health outcomes.
Bill Number: HR 1300
Title: Prostate-Specific Antigen Screening for High-risk Insured Men Act (PSA Screening for HIM Act)
Status: Introduced in House
Introduced On: February 13, 2025
Classification: Bill
The PSA Screening for HIM Act aims to improve prostate cancer screening for high-risk insured men. The legislation seeks to ensure that individuals who are at increased risk for prostate cancer receive appropriate screening through prostate-specific antigen (PSA) tests. This initiative is part of a broader effort to enhance preventive healthcare measures and early detection of prostate cancer, which can significantly impact treatment outcomes.
While the full text of the bill has not been provided, the following key elements can be anticipated based on the title and purpose:
The bill has garnered support from a diverse group of sponsors, including:
- Primary Sponsor: Neal P. Dunn
- Cosponsors: A total of 22 cosponsors, including notable representatives such as Yassamin Ansari, Chris Pappas, and Rashida Tlaib, reflecting bipartisan support for the initiative.
The PSA Screening for HIM Act represents a significant step towards enhancing preventive healthcare for high-risk men regarding prostate cancer. By ensuring access to necessary screenings, the bill aims to facilitate early detection and improve health outcomes for this vulnerable population. As the legislative process unfolds, further details will emerge regarding the specific provisions and implications of the bill.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.